{"id":"NCT01363700","sponsor":"Santen Pharmaceutical Co., Ltd.","briefTitle":"Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis","officialTitle":"Double-masked, Comparison Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis - Phase 3, Confirmatory Study -","status":"COMPLETED","phase":"PHASE3","dates":{"start":null,"primaryCompletion":"2012-06","completion":null,"firstPosted":"2011-06-01","resultsPosted":"2014-11-05","lastUpdate":"2014-11-19"},"enrollment":87,"design":{"allocation":null,"model":null,"masking":null,"primaryPurpose":null},"conditions":["Allergic Conjunctivitis"],"interventions":[{"type":"DRUG","name":"DE-114 ophthalmic solution","otherNames":["Epinastine ophthalmic solution"]},{"type":"DRUG","name":"Placebo ophthalmic solution","otherNames":[]},{"type":"DRUG","name":"Olopatadine Hydrochloride 0.1% Ophthalmic Solution","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"},{"label":"3","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to demonstrate safety and efficacy of DE-114 ophthalmic solution compared to its Placebo and Olopatadine hydrochloride 0.1% ophthalmic solution in patients with allergic conjunctivitis.","primaryOutcome":{"measure":"Mean Ocular Itching Score Compared to Placebo Period1","timeFrame":"Visit 5 (3, 5, and 10 minutes post-CAC)","effectByArm":[{"arm":"Epinastine (DE-114) Ophthalmic Solution","deltaMin":0.4,"sd":0.1},{"arm":"Placebo Ophthalmic Solution","deltaMin":1.7,"sd":0.1}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["25163405"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":87},"commonTop":[]}}